CTNM
Contineum TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.3.
What can break
Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
Momentum
48
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $19.00 · Bear $8.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $20.33
Why
Momentum48 · Δ7d -19.9
Value41 · Δ7d +0.1
Sentiment58 · Δ7d +9.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-19.9
Δ21d
-19.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendImproving
Δ7d
+9.3
Δ21d
+12.2
Why this grade
Composite grade C. Momentum 48.3 / Value 41.1 / Sentiment 58.4
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$462.84M
Beta
-
Shares Out
36.86M
P/E (TTM) · Derived
-5.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.28
Rev YoY
-100.0%
EPS YoY
-14.0%
Gross Margin
-
Op Margin
-
Net Debt
-$204.76M
Current Ratio
29.07
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology